IsoTis snaps up GenSci after Osteotech settlement
This article was originally published in Clinica
Executive Summary
The sales and marketing synergies offered by a merger with GenSci OrthoBiologics and underlying industry growth should lead to IsoTis reaching profitability in 2005. So said the Swiss-Dutch company said after announcing its intention to acquire the Irvine, California operating subsidiary of Toronto, Canada-based bioimplant firm GenSci Regeneration Sciences. The firms will be targeting the bone void filler market, which was worth around $300m in 2002.
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.